A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes

Trial Profile

A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs LY 2382770 (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 18 Sep 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 25 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 May 2014 Planned End Date changed from 1 Nov 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top